BIOMERICA, INC. (NASDAQ:BMRA) Files An 8-K Regulation FD Disclosure

BIOMERICA, INC. (NASDAQ:BMRA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

Story continues below

     On September 1, 2020, Biomerica, Inc. (“the “Company”) presented an investor presentation to the investment community.  The investor presentation is attached hereto as Exhibit 99.1.

     The investor presentation is being furnished to General Instruction B.2 of Form 8-K and is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor is it subject to the liabilities of that section or deemed incorporated by reference in any filing by the Company under the Exchange Act unless specifically identified therein as being incorporated therein by reference.

Item 9.01  Financial Statements and Exhibits

(d)  Exhibits


Number           Description

99.1                 Investor Presentation


To view the full exhibit click here


Biomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company’s medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians’ offices and over-the-counter drugstores). The Company operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company’s diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations. The Company primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The Company’s diagnostic products use immunoassay technology.

An ad to help with our costs